Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Interaction Between the Haptoglobin Genotype and Vitamin E on Cardiovascular Disease in Diabetes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Current Science Country of Publication: United States NLM ID: 101093791 Publication Model: Print Cited Medium: Internet ISSN: 1539-0829 (Electronic) Linking ISSN: 15344827 NLM ISO Abbreviation: Curr Diab Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: Philadelphia, PA : Current Science, c2001-
    • Subject Terms:
    • Abstract:
      Purpose of Review: Despite compelling evidence regarding the importance of oxidant stress in the development of vascular complications and observational studies suggesting that vitamin E may be protective from these complications, multiple clinical trials have failed to show benefit from vitamin E supplementation in the prevention of vascular complications in diabetes. One possible explanation for this failure of vitamin E may have been inappropriate patient selection. This review seeks to provide the clinical evidence and mechanistic basis for why a subset of individuals defined by their haptoglobin (Hp) genotype may derive cardiovascular protection by vitamin E supplementation.
      Recent Findings: Clinical trial data from the HOPE, ICARE, and WHS studies is presented showing a pharmacogenomic interaction between the Hp genotype and vitamin E on the development of CVD. Specifically, in individuals with diabetes and the Hp2-2 genotype, vitamin E has been shown to be associated with an approximately 35% reduction in CVD. Cardioprotection by vitamin E in individuals with the Hp2-2 genotype appears to be mediated in part by an improvement in HDL functionality as demonstrated in three independent trials in both type 1 diabetes and type 2 diabetes. Vitamin E may provide benefit in reducing CVD in Hp2-2 individuals with diabetes. However, in order for this pharmacogenomic algorithm to be accepted as a standard of care and used clinically, an additional large prospective study will need to be performed.
    • References:
      N Engl J Med. 1989 Apr 6;320(14):915-24. (PMID: 2648148)
      JAMA. 2008 Nov 12;300(18):2123-33. (PMID: 18997197)
      J Am Coll Cardiol. 2002 Dec 4;40(11):1984-90. (PMID: 12475459)
      N Engl J Med. 1993 May 20;328(20):1444-9. (PMID: 8479463)
      Eur Heart J. 1998 Feb;19 Suppl A:A31-5. (PMID: 9519340)
      Diabetes. 2008 Oct;57(10):2794-800. (PMID: 18599520)
      N Engl J Med. 2016 Aug 4;375(5):454-63. (PMID: 27518663)
      Photochem Photobiol. 1974 Dec;20(6):505-9. (PMID: 4457927)
      Diabetes. 2005 Sep;54(9):2802-6. (PMID: 16123372)
      J Mol Biol. 1984 Apr 5;174(2):343-68. (PMID: 6716482)
      J Nutr. 2005 Mar;135(3):363-6. (PMID: 15735064)
      Nat Clin Pract Endocrinol Metab. 2006 Sep;2(9):504-11. (PMID: 16957764)
      J Lipid Res. 2013 Sep;54(9):2307-14. (PMID: 23505320)
      J Am Coll Cardiol. 2016 May 31;67(21):2553-4. (PMID: 27230052)
      Diabetes Care. 2003 Sep;26(9):2628-31. (PMID: 12941730)
      Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):341-7. (PMID: 18032779)
      Fed Proc. 1977 May;36(6):1906-10. (PMID: 323068)
      Nature. 2001 Jan 11;409(6817):198-201. (PMID: 11196644)
      Biochim Biophys Acta. 1986 Aug 7;860(1):84-90. (PMID: 3089279)
      Circ Res. 2007 Jul 6;101(1):106-10. (PMID: 17525367)
      Nature. 1969 Sep 13;223(5211):1163-5. (PMID: 5810694)
      Circ Res. 2003 Jun 13;92(11):1193-200. (PMID: 12750308)
      Diabetes Care. 2004 Nov;27(11):2767. (PMID: 15505023)
      N Engl J Med. 2000 Jan 20;342(3):154-60. (PMID: 10639540)
      Adv Hum Genet. 1982;12:189-261, 453-4. (PMID: 6751044)
      Blood. 1961 Jan;17:45-53. (PMID: 13727037)
      Lancet. 2000 Oct 7;356(9237):1213-8. (PMID: 11072938)
      Ann Intern Med. 2005 Jan 4;142(1):37-46. (PMID: 15537682)
      Diabetes Care. 2003 Dec;26(12):3264-72. (PMID: 14633812)
      Arterioscler Thromb Vasc Biol. 2000 Jul;20(7):1716-23. (PMID: 10894808)
      Atherosclerosis. 1996 Jul;124 Suppl:S11-20. (PMID: 8831911)
      Atherosclerosis. 2010 Jul;211(1):25-7. (PMID: 20223458)
      Cytobios. 2000;101(398):145-50. (PMID: 10755213)
      N Engl J Med. 1993 May 20;328(20):1450-6. (PMID: 8479464)
      Arch Intern Med. 1998 Mar 23;158(6):668-75. (PMID: 9521232)
      J Lipid Res. 1992 Mar;33(3):385-97. (PMID: 1314881)
      JAMA. 2005 Jul 6;294(1):56-65. (PMID: 15998891)
      Clin Exp Immunol. 1991 Mar;83(3):488-91. (PMID: 1706240)
      J Biol Chem. 2007 Aug 10;282(32):23698-707. (PMID: 17556366)
      Clin Chem. 1996 Oct;42(10):1589-600. (PMID: 8855140)
    • Contributed Indexing:
      Keywords: Cardiovascular disease*; Haptoglobin*; High-density lipoproteins*; Oxidative stress*; Vitamin E*
    • Accession Number:
      0 (Antioxidants)
      0 (Haptoglobins)
      1406-18-4 (Vitamin E)
    • Publication Date:
      Date Created: 20170429 Date Completed: 20170712 Latest Revision: 20181202
    • Publication Date:
      20220902
    • Accession Number:
      10.1007/s11892-017-0868-1
    • Accession Number:
      28451949